RxDoctor Payments Data

Jennifer Garrison, DO

Family Medicine · Katy, TXNPI 1396901138

Payments from drug & device makers

$8,493in general payments, 2019–2025

Across 487 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AstraZeneca$676
  • Pfizer$665
  • Lilly USA, LLC$594
  • Corcept Therapeutics$526
  • Abbott$505
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$8,44299%
  • Education$521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,493 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$73,980
Medicare patients
235
Services billed
663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$132,115
FarxigaDapagliflozin Propanediol54$61,032
JardianceEmpagliflozin42$54,783
MounjaroTirzepatide18$32,092
JanuviaSitagliptin Phosphate13$20,529
EliquisApixaban17$20,226
MyrbetriqMirabegron15$16,771
Tresiba Flextouch U-100Insulin Degludec28$16,609
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$14,782
Atorvastatin Calcium453$4,801
Rosuvastatin Calcium218$3,283
Ezetimibe81$2,996
Levothyroxine Sodium331$2,702
Valsartan82$2,566
Pravastatin Sodium131$2,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,558$132,11577 claims
AstraZenecaFarxiga$676$61,03254 claims
Boehringer IngelheimJardiance$162$54,78342 claims
Lilly USA, LLCMounjaro$594$32,09218 claims
MerckJanuvia$187$20,52913 claims
PfizerEliquis$665$20,22617 claims
Astellas Pharma US IncMyrbetriq$98$16,77115 claims
AbbVieSynthroid$353$1,62538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Katy

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →